Ribociclib followed as the second CDK4/6 inhibitor approved in 2017, and abemaciclib was the third FDA-approved CDK4/6 inhibitor, indicated for use with aromatase inhibitors or fulvestrant in treating advanced or metastatic HR-positive/HER2-negative breast cancer (47). This evidence concerns the gene CDK4 and breast cancer.